Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin Solomon, Benjamin Besse, Todd Michael Bauer et al. · The Lancet Oncology · 2018
Cited by 790 works. doi:10.1016/s1470-2045(18)30649-1
Authors
- Benjamin Solomon
- Benjamin Besse
- Todd Michael Bauer
- Enriqueta Felip
- Ross Andrew Soo
- D. Ross Camidge
- Rita Chiari
- Alessandra Bearz
- Chia‐Chi Lin
- Shirish M. Gadgeel
- Gregory J. Riely
- Eng Huat Tan
- Takashi Seto
- Leonard Philip James
- Jill S. Clancy
- Antonello Abbattista
- Jean-François Martini
- Joseph Chen
- Gerson Peltz
- Holger C. Thurm
References
- Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
- First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
- Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
- EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
- Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
- RET, ROS1 and ALK fusions in lung cancer
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis